

FOI REF: 26/046

10th February 2026

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Acute Myeloid Leukaemia (AML) Patients

- 1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months**
 - a. Of these patients how many are refractory/relapsed (R/R)?**
 - b. How many of the R/R patients were FLT3 positive?**

East Sussex Healthcare NHS Trust can confirm that we had 8 diagnoses in 2024 and 6 in 2025. However, this is based on the number that have been manually entered into the Cancer Registry, but this is not reflective of the annual number of diagnoses in total due to the way in which blood cancers are identified.

To enable the Trust to provide this information would require a manual review of all referrals into Haematology, during the period requested, which we estimate would take many weeks. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

Cont.../

2. How many patients have been treated for AML in the latest 12 months with the following treatments

• Venetoclax with azacitidine	8
• Midostaurin	0
• Quizartinib	0
• Gemtuzumab	0
• Ivosidenib with azacitidine	1
• Liposomal cytarabine–daunorubicin	0
• Oral azacitidine	0
• Gilteritinib	0
• Palliative care	Section 12 applied, please see below
• Enrolled in a clinical trial	2

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

3. How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use)).

• Venetoclax with azacitidine	8
• Midostaurin	0
• Quizartinib	0
• Gemtuzumab	0
• Ivosidenib with azacitidine	0
• Liposomal cytarabine–daunorubicin	0
• Oral azacitidine	0
• Gilteritinib	0
• Palliative care	Section 12 applied, please refer to question 2
• Enrolled in a clinical trial	1

4. Of your AML patient how many were tested as below in the last 12 months

- **Received an FLT3 mutation test when they were diagnosed**
- **Received an FLT3 mutation test when their disease relapsed**
- **Received an FLT3 mutation test when their disease became refractory**

No patients have been treated for AML in the latest 12 months on a clinical trial.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net